Form 4: Alnylam Pharmaceuticals Executive Acquires Shares and Stock Options

Robert W. Hesslein, EVP, CLO and Secretary of Alnylam Pharmaceuticals, reports acquisition of common stock and stock options.

Summary

• Robert W. Hesslein, an executive at Alnylam Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Hesslein acquired 757 shares of common stock represented by restricted stock units (RSUs) at a price of $0.0.
• These RSUs vest over a three-year period, with one-third vesting annually, contingent upon continuous service.
• Hesslein also acquired stock options for 1,529 shares of common stock at an exercise price of $243.53.
• These options vest over four years, with 25% vesting on the first anniversary and the remainder in equal quarterly installments.
• Following these transactions, Hesslein directly owns 8,002 shares of common stock and stock options for 1,529 shares.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting transactions. The sentiment is slightly positive as it reflects ongoing executive compensation, which is a normal business practice.

Positives

• The acquisition of shares and stock options by an executive could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. These filings are closely watched by investors for signals about management's confidence in the company.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders.
• Vesting schedules for stock options and RSUs, such as the three-year and four-year vesting periods described in the document, are typical in the industry.

Stakeholder Impact

• The transactions reported in the Form 4 filing may have a minor impact on shareholders by slightly diluting the ownership base as RSUs vest and options are exercised.

Key Dates